SG11202008897SA - C3-binding agents and methods of use thereof - Google Patents
C3-binding agents and methods of use thereofInfo
- Publication number
- SG11202008897SA SG11202008897SA SG11202008897SA SG11202008897SA SG11202008897SA SG 11202008897S A SG11202008897S A SG 11202008897SA SG 11202008897S A SG11202008897S A SG 11202008897SA SG 11202008897S A SG11202008897S A SG 11202008897SA SG 11202008897S A SG11202008897S A SG 11202008897SA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- binding agents
- binding
- agents
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862652253P | 2018-04-03 | 2018-04-03 | |
| PCT/US2019/025123 WO2019195136A1 (en) | 2018-04-03 | 2019-04-01 | C3-binding agents and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202008897SA true SG11202008897SA (en) | 2020-10-29 |
Family
ID=66630340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202008897SA SG11202008897SA (en) | 2018-04-03 | 2019-04-01 | C3-binding agents and methods of use thereof |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11136381B2 (en) |
| EP (1) | EP3790897A1 (en) |
| KR (1) | KR20200138290A (en) |
| CN (1) | CN112105638A (en) |
| AR (1) | AR117565A1 (en) |
| AU (1) | AU2019248557A1 (en) |
| BR (1) | BR112020019907A2 (en) |
| CA (1) | CA3093356A1 (en) |
| CL (2) | CL2020002522A1 (en) |
| CO (1) | CO2020013468A2 (en) |
| IL (1) | IL277404A (en) |
| MX (1) | MX2020010323A (en) |
| PE (1) | PE20212132A1 (en) |
| PH (1) | PH12020500664A1 (en) |
| SG (1) | SG11202008897SA (en) |
| WO (1) | WO2019195136A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112105638A (en) | 2018-04-03 | 2020-12-18 | 恩格姆生物制药公司 | C3 binding agents and methods of use thereof |
| WO2021226442A2 (en) | 2020-05-08 | 2021-11-11 | Ngm Biopharmaceuticals, Inc. | Therapeutic uses of c3-binding agents |
| EP4213808A1 (en) * | 2020-09-21 | 2023-07-26 | Apellis Pharmaceuticals, Inc. | Methods of treating eye disorders |
| US20230257455A1 (en) | 2021-12-22 | 2023-08-17 | Cdr-Life Ag | Anti-c3 antibodies and antigen-binding fragments thereof and their uses for treating eye or ocular diseases |
| CN117447601B (en) * | 2023-12-22 | 2024-03-08 | 北京索莱宝科技有限公司 | Antibodies to porcine IgM, antibody compositions and uses thereof |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000015259A1 (en) * | 1998-09-10 | 2000-03-23 | The University Of Virginia Patent Foundation | Antibodies to c3b(i) for delivery of diagnostic and therapeutic agents to cancer cells |
| AU2003271681A1 (en) * | 2002-10-04 | 2004-04-23 | Sanquin Blood Supply Foundation Amsterdam | Monoclonal antibody anti-c3-2 directed against the third component of complement (c3) and its use in methods to inhibit complement activation |
| US7816497B2 (en) | 2002-10-30 | 2010-10-19 | University Of Kentucky | Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration |
| EP2267032A3 (en) * | 2002-11-08 | 2011-11-09 | Ablynx N.V. | Method of administering therapeutic polypeptides, and polypeptides therefor |
| US20090004183A1 (en) | 2004-07-23 | 2009-01-01 | Taylor Ronald P | Compositions and Methods for Regulating the Alternative Pathway of Complement |
| JP2008527005A (en) | 2005-01-14 | 2008-07-24 | ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、カリフォルニア | Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders |
| US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| UA99591C2 (en) | 2005-11-04 | 2012-09-10 | Дженентек, Инк. | Use of complement pathway inhibitors to treat ocular diseases |
| AU2008214359B2 (en) | 2007-02-05 | 2014-01-16 | Apellis Pharmaceuticals, Inc. | Local complement inhibition for treatment of complement-mediated disorders |
| US9745367B2 (en) | 2007-03-23 | 2017-08-29 | Novelmed Theraputics, Inc. | Alternative pathway specific antibodies for treating arthritis |
| US8192742B2 (en) | 2007-03-23 | 2012-06-05 | NovelMed Therapeutics | Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof |
| KR101572700B1 (en) | 2007-06-07 | 2015-11-30 | 제넨테크, 인크. | C3b antibodies and methods for the prevention and treatment of complement-associated disorders |
| US20100291106A1 (en) | 2009-05-06 | 2010-11-18 | Novartis Ag | Compositions and methods for antibodies targeting complement protein c3b |
| EP2433953B1 (en) | 2009-05-20 | 2015-07-08 | Toray Industries, Inc. | Cell membrane-permeable peptides |
| WO2010135717A2 (en) | 2009-05-21 | 2010-11-25 | Potentia Pharmaceuticals, Inc. | Complement assays and uses thereof |
| US20130177567A1 (en) | 2010-05-18 | 2013-07-11 | Sydansk Universitet | Novel c3c epitope, antibodies binding thereto, and use thereof |
| USRE49339E1 (en) | 2010-06-22 | 2022-12-20 | The Regents Of The University Of Colorado, A Body Corporate | Antibodies to the C3D fragment of complement component 3 |
| AU2013243574B2 (en) | 2012-04-03 | 2017-12-07 | Novelmed Therapeutics, Inc | Humanized and chimeric anti-factor C3 antibodies and uses thereof |
| WO2015099838A2 (en) | 2013-12-24 | 2015-07-02 | Novelmed Therapeutics, Inc. | Compositions and methods of treating ocular diseases |
| MX2016014504A (en) | 2014-05-05 | 2017-05-23 | Regeneron Pharma | Humanized c5 and c3 animals. |
| US10815276B2 (en) | 2014-05-21 | 2020-10-27 | Entrada Therapeutics, Inc. | Cell penetrating peptides and methods of making and using thereof |
| US20180346531A1 (en) | 2015-09-15 | 2018-12-06 | Regents Of The University Of California | Compositions and methods for delivering biotherapeutics |
| JP6968787B2 (en) | 2015-10-07 | 2021-11-17 | アペリス・ファーマシューティカルズ・インコーポレイテッドApellis Pharmaceuticals, Inc. | Dosing regimen |
| JP2020528082A (en) | 2017-07-17 | 2020-09-17 | ロイズマン，キース | Topical delivery of therapeutic agents using cell-permeable peptides for the treatment of age-related macular degeneration and other eye diseases |
| CN112105638A (en) | 2018-04-03 | 2020-12-18 | 恩格姆生物制药公司 | C3 binding agents and methods of use thereof |
-
2019
- 2019-04-01 CN CN201980027315.6A patent/CN112105638A/en active Pending
- 2019-04-01 BR BR112020019907-9A patent/BR112020019907A2/en unknown
- 2019-04-01 WO PCT/US2019/025123 patent/WO2019195136A1/en unknown
- 2019-04-01 AU AU2019248557A patent/AU2019248557A1/en active Pending
- 2019-04-01 KR KR1020207030405A patent/KR20200138290A/en unknown
- 2019-04-01 SG SG11202008897SA patent/SG11202008897SA/en unknown
- 2019-04-01 CA CA3093356A patent/CA3093356A1/en active Pending
- 2019-04-01 PE PE2020001505A patent/PE20212132A1/en unknown
- 2019-04-01 EP EP19725880.9A patent/EP3790897A1/en active Pending
- 2019-04-01 MX MX2020010323A patent/MX2020010323A/en unknown
- 2019-04-01 AR ARP190100853A patent/AR117565A1/en unknown
- 2019-04-01 US US16/371,684 patent/US11136381B2/en active Active
-
2020
- 2020-09-16 IL IL277404A patent/IL277404A/en unknown
- 2020-09-29 CL CL2020002522A patent/CL2020002522A1/en unknown
- 2020-10-01 PH PH12020500664A patent/PH12020500664A1/en unknown
- 2020-10-26 CO CONC2020/0013468A patent/CO2020013468A2/en unknown
-
2021
- 2021-08-02 CL CL2021002039A patent/CL2021002039A1/en unknown
- 2021-08-19 US US17/406,991 patent/US11767359B2/en active Active
-
2023
- 2023-08-10 US US18/447,741 patent/US20230382985A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CL2020002522A1 (en) | 2021-02-26 |
| AU2019248557A1 (en) | 2020-09-24 |
| IL277404A (en) | 2020-11-30 |
| JP2021520195A (en) | 2021-08-19 |
| PH12020500664A1 (en) | 2021-06-07 |
| TW202003559A (en) | 2020-01-16 |
| US20190322730A1 (en) | 2019-10-24 |
| EP3790897A1 (en) | 2021-03-17 |
| KR20200138290A (en) | 2020-12-09 |
| CL2021002039A1 (en) | 2022-04-01 |
| CA3093356A1 (en) | 2019-10-10 |
| BR112020019907A2 (en) | 2021-01-05 |
| CN112105638A (en) | 2020-12-18 |
| WO2019195136A1 (en) | 2019-10-10 |
| PE20212132A1 (en) | 2021-11-05 |
| RU2020135712A (en) | 2022-05-04 |
| US20220119508A1 (en) | 2022-04-21 |
| US11767359B2 (en) | 2023-09-26 |
| US11136381B2 (en) | 2021-10-05 |
| CO2020013468A2 (en) | 2020-11-10 |
| MX2020010323A (en) | 2021-01-08 |
| AR117565A1 (en) | 2021-08-18 |
| US20230382985A1 (en) | 2023-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276731A (en) | Anti-cd73 antibodies and methods of use thereof | |
| IL271025A (en) | Multibiotic agents and methods of using the same | |
| SG11202010909RA (en) | Anti-msr1 antibodies and methods of use thereof | |
| IL277404A (en) | C3-binding agents and methods of use thereof | |
| IL278821A (en) | Anti-sirpa antibodies and methods of use thereof | |
| IL279475A (en) | Ectonucleotidase inhibitors and methods of use thereof | |
| IL276687A (en) | Trialkyne linking agents and methods of use | |
| IL270214A (en) | Anti-sortilin antibodies and methods of use thereof | |
| IL283387A (en) | Diarylhydantoin compounds and methods of use thereof | |
| IL289748A (en) | Heterodimers and methods of use thereof | |
| ZA202100780B (en) | Bismuth-thiol compositions and methods of use | |
| IL276135A (en) | Compositions and methods of use | |
| IL281438A (en) | Pyridazinones and methods of use thereof | |
| IL279648A (en) | Anti-sirp-beta1 antibodies and methods of use thereof | |
| IL277212A (en) | Anti-klk5 antibodies and methods of use | |
| IL283782A (en) | Anellosomes and methods of use | |
| IL283884A (en) | Anti-il-36 antibodies and methods of use thereof | |
| IL280338A (en) | Anti-siglec-5 antibodies and methods of use thereof | |
| EP3749691A4 (en) | Angptl8-binding agents and methods of use thereof | |
| IL274433A (en) | Fulvestrant formulations and methods of their use | |
| IL279227A (en) | Anti-siglec-7 antibodies and methods of use thereof | |
| IL276053A (en) | Therapeutic-gard and method of use thereof | |
| IL283231A (en) | Dpep-1 binding agents and methods of use | |
| IL284689A (en) | Endoscopic device and methods of use thereof | |
| GB201610176D0 (en) | Imaging agents and methods of use |